Louise Chen
Stock Analyst at Scotiabank
(3.13)
# 1,176
Out of 4,944 analysts
299
Total ratings
45.1%
Success rate
0.16%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $20.40 | +292.16% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.70 | +429.41% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $13.73 | +1.97% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.55 | +674.19% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.61 | +166.86% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $48.16 | +14.20% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $3.81 | +293.70% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $44.64 | +12.01% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.75 | +160.87% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $11.98 | +41.90% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $46.15 | +51.68% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $12.24 | +308.50% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $15.82 | +89.63% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $35.63 | +54.36% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.94 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $50.90 | +214.34% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.55 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.16 | +78.86% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $174.42 | +23.27% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.43 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $82.71 | +87.40% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.96 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $660.49 | +33.99% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.52 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.89 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.20 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.29 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $63.25 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $201.47 | -0.73% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.79 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.63 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.90 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.16 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $561.55 | +64.72% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.85 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.09 | +2,003.56% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.36 | +111.86% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $4.24 | +489.62% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.07 | +211.14% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.63 | +219.90% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.14 | +338.60% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.35 | +2,489.93% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.59 | +65,154,340.15% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $376.20 | -31.42% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $17.21 | -12.84% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.40 | +3,471.43% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.35 | +1,381.48% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.28 | +518.13% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $20.40
Upside: +292.16%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.70
Upside: +429.41%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $13.73
Upside: +1.97%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.55
Upside: +674.19%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.61
Upside: +166.86%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $48.16
Upside: +14.20%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $3.81
Upside: +293.70%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $44.64
Upside: +12.01%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.75
Upside: +160.87%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $11.98
Upside: +41.90%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $46.15
Upside: +51.68%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $12.24
Upside: +308.50%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $15.82
Upside: +89.63%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $35.63
Upside: +54.36%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.94
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $50.90
Upside: +214.34%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.55
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.16
Upside: +78.86%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $174.42
Upside: +23.27%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.43
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $82.71
Upside: +87.40%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.96
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $660.49
Upside: +33.99%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.89
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.20
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.29
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $63.25
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $201.47
Upside: -0.73%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.79
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.63
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.90
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.16
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $561.55
Upside: +64.72%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.85
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.09
Upside: +2,003.56%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.36
Upside: +111.86%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $4.24
Upside: +489.62%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.07
Upside: +211.14%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.63
Upside: +219.90%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.14
Upside: +338.60%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.35
Upside: +2,489.93%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.59
Upside: +65,154,340.15%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $376.20
Upside: -31.42%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $17.21
Upside: -12.84%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.40
Upside: +3,471.43%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.35
Upside: +1,381.48%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.28
Upside: +518.13%